NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
- 29 November 2018
- journal article
- research article
- Published by Elsevier BV in Cell
- Vol. 175 (7), 1744-1755.e15
- https://doi.org/10.1016/j.cell.2018.10.028
Abstract
No abstract availableKeywords
Funding Information
- Dutch Cancer Society (2014-7146, 2014-6696)
- Innate Pharma
- NIH (NIH-R01 CA178613-05)
- Amy and Barry Baker Lab
This publication has 58 references indexed in Scilit:
- HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+T lymphocytesProceedings of the National Academy of Sciences, 2011
- Therapeutic cancer vaccines: are we there yet?Immunological Reviews, 2010
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- An Unexpectedly Large Polyclonal Repertoire of HPV-Specific T Cells Is Poised for Action in Patients with Cervical CancerCancer Research, 2010
- Memory Inflation during Chronic Viral Infection Is Maintained by Continuous Production of Short-Lived, Functional T CellsImmunity, 2008
- Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA‐DQ and –DP as a restriction elementInternational Journal of Cancer, 2007
- The role of TCR stimulation and TGF‐β in controlling the expression of CD94/NKG2A receptors on CD8 T cellsEuropean Journal of Immunology, 2005
- Recognition of the Class Ib Molecule Qa-1b by Putative Activating Receptors Cd94/Nkg2c and Cd94/Nkg2e on Mouse Natural Killer CellsThe Journal of Experimental Medicine, 1999
- Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative TumorsThe Journal of Experimental Medicine, 1998
- NKG2A Complexed with CD94 Defines a Novel Inhibitory Natural Killer Cell ReceptorThe Journal of Experimental Medicine, 1997